Neurexin 3 (NRXN3) (N-Term) Peptide
NRXN3
Reactivité: Humain
Hôte: Synthetic
BP, WB
N° du produit ABIN5511400
Aperçu rapide pour Neurexin 3 (NRXN3) (N-Term) Peptide (ABIN5511400)
Antigène
Neurexin 3 (NRXN3)
Origine
Humain
Source
Synthetic
Application
Blocking Peptide (BP), Western Blotting (WB)
-
-
Protein Region
- N-Term
-
Séquence
- SPGSHSQHEH HFHGSKHHSV PISIYRSPVS LRGGHAGATY IFGKSGGLIL
-
Attributs du produit
- This is a synthetic peptide designed for use in combination with anti- NRXN3 Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
-
-
-
Indications d'application
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Stock
- -20 °C
-
Stockage commentaire
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- Neurexin 3 (NRXN3)
-
Sujet
-
This gene encodes a member of a family of proteins that function in the nervous system as receptors and cell adhesion molecules. Extensive alternative splicing and the use of alternative promoters results in multiple transcript variants and protein isoforms for this gene, but the full-length nature of many of these variants has not been determined. Transcripts that initiate from an upstream promoter encode alpha isoforms, which contain epidermal growth factor-like (EGF-like) sequences and laminin G domains. Transcripts initiating from the downstream promoter encode beta isoforms, which lack EGF-like sequences. Genetic variation at this locus has been associated with a range of behavioral phenotypes, including alcohol dependence and autism spectrum disorder.
Alias Symbols: C14orf60
Protein Size: 637 -
ID gène
- 9369
-
NCBI Accession
- NM_004796, NP_001098720
-
UniProt
- Q9HDB5
Antigène
-
Vous êtes ici:
